PURPOSE: To document the penetration of clinical trial results, practice guidelines, and appropriateness criteria into national practice, we compared the use of components of staging and treatment for lung cancer among patients treated in 2006-2007 with those used in patients treated in 1998-1999. METHODS AND MATERIALS: Patient, staging work-up, and treatment characteristics were extracted from the process survey database of the Quality Research in Radiation Oncology (QRRO), consisting of records of 340 patients with locally advanced non-small cell lung cancer (LA-NSCLC) at 44 institutions and of 144 patients with limited-stage small cell lung cancer (LS-SCLC) at 39 institutions. Data were compared for patients treated in 2006-2007 versus those for patients treated in 1998-1999. RESULTS: Use of all recommended procedures for staging and treatment was more common in 2006-2007. Specifically, disease was staged with brain imaging (magnetic resonance imaging or computed tomography) and whole-body imaging (positron emission tomography or bone scanning) in 66% of patients with LA-NSCLC in 2006-2007 (vs 42% in 1998-1999, P=.0001) and in 84% of patients with LS-SCLC in 2006-2007 (vs 58.3% in 1998-1999, P=.0011). Concurrent chemoradiation was used for 77% of LA-NSCLC patients (vs 45% in 1998-1999, P<.0001) and for 90% of LS-SCLC patients (vs 62.5% in 1998-1999, P<.0001). Use of the recommended radiation dose (59-74 Gy for NSCLC and 60-70 Gy as once-daily therapy for SCLC) did not change appreciably, being 88% for NSCLC in both periods and 51% (2006-2007) versus 43% (1998-1999) for SCLC. Twice-daily radiation for SCLC was used for 21% of patients in 2006-2007 versus 8% in 1998-1999. Finally, 49% of patients with LS-SCLC received prophylactic cranial irradiation (PCI) in 2006-2007 (vs 21% in 1998-1999). CONCLUSIONS: Although adherence to all quality indicators improved over time, brain imaging and recommended radiation doses for stage III NSCLC were used in <90% of cases. Use of full thoracic doses and PCI for LS-SCLC also requires improvement. Published by Elsevier Inc.
PURPOSE: To document the penetration of clinical trial results, practice guidelines, and appropriateness criteria into national practice, we compared the use of components of staging and treatment for lung cancer among patients treated in 2006-2007 with those used in patients treated in 1998-1999. METHODS AND MATERIALS: Patient, staging work-up, and treatment characteristics were extracted from the process survey database of the Quality Research in Radiation Oncology (QRRO), consisting of records of 340 patients with locally advanced non-small cell lung cancer (LA-NSCLC) at 44 institutions and of 144 patients with limited-stage small cell lung cancer (LS-SCLC) at 39 institutions. Data were compared for patients treated in 2006-2007 versus those for patients treated in 1998-1999. RESULTS: Use of all recommended procedures for staging and treatment was more common in 2006-2007. Specifically, disease was staged with brain imaging (magnetic resonance imaging or computed tomography) and whole-body imaging (positron emission tomography or bone scanning) in 66% of patients with LA-NSCLC in 2006-2007 (vs 42% in 1998-1999, P=.0001) and in 84% of patients with LS-SCLC in 2006-2007 (vs 58.3% in 1998-1999, P=.0011). Concurrent chemoradiation was used for 77% of LA-NSCLCpatients (vs 45% in 1998-1999, P<.0001) and for 90% of LS-SCLCpatients (vs 62.5% in 1998-1999, P<.0001). Use of the recommended radiation dose (59-74 Gy for NSCLC and 60-70 Gy as once-daily therapy for SCLC) did not change appreciably, being 88% for NSCLC in both periods and 51% (2006-2007) versus 43% (1998-1999) for SCLC. Twice-daily radiation for SCLC was used for 21% of patients in 2006-2007 versus 8% in 1998-1999. Finally, 49% of patients with LS-SCLC received prophylactic cranial irradiation (PCI) in 2006-2007 (vs 21% in 1998-1999). CONCLUSIONS: Although adherence to all quality indicators improved over time, brain imaging and recommended radiation doses for stage III NSCLC were used in <90% of cases. Use of full thoracic doses and PCI for LS-SCLC also requires improvement. Published by Elsevier Inc.
Authors: Eric C Schneider; Jennifer L Malin; Katherine L Kahn; Ezekiel J Emanuel; Arnold M Epstein Journal: J Clin Oncol Date: 2004-08-01 Impact factor: 44.544
Authors: Cheryl Crozier; Beth Erickson-Wittmann; Benjamin Movsas; Jean Owen; Najma Khalid; J Frank Wilson Journal: J Healthc Qual Date: 2011-09 Impact factor: 1.095
Authors: Mitchell Machtay; Kyounghwa Bae; Benjamin Movsas; Rebecca Paulus; Elizabeth M Gore; Ritsuko Komaki; Kathy Albain; William T Sause; Walter J Curran Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-25 Impact factor: 7.038
Authors: K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: B Movsas; J Moughan; R Komaki; H Choy; R Byhardt; C Langer; M Goldberg; M Graham; D Ettinger; D Johnstone; R Abrams; R Munden; G Starkschall; J Owen Journal: J Clin Oncol Date: 2003-11-03 Impact factor: 44.544
Authors: Brian E Lally; Ann M Geiger; James J Urbanic; Jerome M Butler; Stacy Wentworth; Michael C Perry; Lynn D Wilson; Janet K Horton; Frank C Detterbeck; Antonius A Miller; Charles R Thomas; A William Blackstock Journal: Lung Cancer Date: 2008-10-02 Impact factor: 5.705
Authors: Amir Zahra; Tangel Chang; Taher Abu Hejleh; Muhammad Furqan; Gerald H Clamon; Sudershan K Bhatia; John M Watkins; Sarah L Mott; Logan L Ahmann; Kellie L Bodeker; Douglas R Spitz; John M Buatti; Bryan G Allen Journal: J Oncol Transl Res Date: 2016-07-26
Authors: Leah M Backhus; Farhood Farjah; Thomas K Varghese; Aaron M Cheng; Xiao-Hua Zhou; Douglas E Wood; Larry Kessler; Steven B Zeliadt Journal: J Clin Oncol Date: 2014-09-22 Impact factor: 44.544
Authors: Jean B Owen; Najma Khalid; Alex Ho; Lisa A Kachnic; Ritsuko Komaki; May Lin Tao; Adam Currey; J Frank Wilson Journal: J Oncol Pract Date: 2014-03-18 Impact factor: 3.840
Authors: Benjamin J Resio; Jessica Hoag; Alexander Chiu; Andres Monsalve; Andrew P Dhanasopon; Daniel J Boffa; Justin D Blasberg Journal: J Thorac Dis Date: 2019-03 Impact factor: 2.895
Authors: Corinne Faivre-Finn; Michael Snee; Linda Ashcroft; Wiebke Appel; Fabrice Barlesi; Adityanarayan Bhatnagar; Andrea Bezjak; Felipe Cardenal; Pierre Fournel; Susan Harden; Cecile Le Pechoux; Rhona McMenemin; Nazia Mohammed; Mary O'Brien; Jason Pantarotto; Veerle Surmont; Jan P Van Meerbeeck; Penella J Woll; Paul Lorigan; Fiona Blackhall Journal: Lancet Oncol Date: 2017-06-20 Impact factor: 41.316
Authors: Johanna Ramroth; David J Cutter; Sarah C Darby; Geoff S Higgins; Paul McGale; Mike Partridge; Carolyn W Taylor Journal: Int J Radiat Oncol Biol Phys Date: 2016-07-25 Impact factor: 7.038